502 related articles for article (PubMed ID: 34823857)
1. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
[TBL] [Abstract][Full Text] [Related]
3. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
5. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
[TBL] [Abstract][Full Text] [Related]
6. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
7. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
Skariyachan S; Gopal D; Chakrabarti S; Kempanna P; Uttarkar A; Muddebihalkar AG; Niranjan V
Comput Biol Med; 2020 Nov; 126():104054. PubMed ID: 33074111
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
9. A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism.
Yao Y; Zhang Y; Li Z; Chen Z; Wang X; Li Z; Yu L; Cheng X; Li W; Jiang WJ; Wu HJ; Feng Z; Sun J; Fei T
Biochem Biophys Res Commun; 2023 Oct; 675():113-121. PubMed ID: 37467664
[TBL] [Abstract][Full Text] [Related]
10. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
11. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
[TBL] [Abstract][Full Text] [Related]
12. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
Talluri S
Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
[TBL] [Abstract][Full Text] [Related]
13. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
14. Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2.
Peele KA; Kumar V; Parate S; Srirama K; Lee KW; Venkateswarulu TC
J Pharm Sci; 2021 Jun; 110(6):2346-2354. PubMed ID: 33684397
[TBL] [Abstract][Full Text] [Related]
15. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
Ribone SR; Paz SA; Abrams CF; Villarreal MA
J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
[TBL] [Abstract][Full Text] [Related]
16. In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches.
Zhang C; Liu J; Sui Y; Liu S; Yang M
Sci Rep; 2023 Dec; 13(1):21404. PubMed ID: 38049492
[TBL] [Abstract][Full Text] [Related]
17. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
[TBL] [Abstract][Full Text] [Related]
18. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics.
Piplani S; Singh P; Petrovsky N; Winkler DA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835602
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.
Chandra A; Gurjar V; Qamar I; Singh N
J Biomol Struct Dyn; 2021 Aug; 39(12):4201-4211. PubMed ID: 32462970
[TBL] [Abstract][Full Text] [Related]
20. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches.
Kalhor H; Sadeghi S; Abolhasani H; Kalhor R; Rahimi H
J Biomol Struct Dyn; 2022 Feb; 40(3):1299-1315. PubMed ID: 32969333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]